Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.

abstract：BACKGROUND:Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is used as monotherapy for chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type (WT) KRAS tumors. Although skin toxicities are the most common adverse events associated with EGFR in...

journal_title：Clinical colorectal cancer

authors： Mitchell EP,Piperdi B,Lacouture ME,Shearer H,Iannotti N,Pillai MV,Xu F,Yassine M

更新日期：2011-12-01 00:00:00

abstract：:Several anticancer therapies have been developed to block angiogenesis, a key mechanism in tumor growth and metastasis. The predominantly cytostatic action of these compounds makes an assessment of their clinical activities inadequate if based only on the reduction of the tumor dimensions, as this may not reflect thei...

journal_title：Clinical colorectal cancer

authors： Manzoni M,Comolli G,Torchio M,Mazzini G,Danova M

更新日期：2015-03-01 00:00:00

abstract：:The development of brain metastases originating from colorectal cancer (CRC) is an infrequent phenomenon occurring in < 5% of patients. Yet, it is feasible that physicians will be diagnosing more patients with brain metastases because of the prolonged survival in our current patient population. The anti-angiogenic age...

journal_title：Clinical colorectal cancer

authors： Bhaskara A,Eng C

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:5-Fluorouracil (5-FU) chemotherapy is associated with severe and unpredictable toxicity in a significant proportion of patients. 5,10-Methylenetetrahydrofolate and 5-fluorodeoxyuridine monophosphate bind to thymidylate synthase and together inhibit its function, resulting in cytotoxicity. We hypothesized tha...

journal_title：Clinical colorectal cancer

authors： Yan M,Ho C,Winquist E,Jonker D,Rayson D,Stitt L,Tokmakejian S,Tomiak A,Vincent MD

更新日期：2016-12-01 00:00:00

abstract：:Epidermal growth factor receptor (EGFR) has been validated as an important target in the treatment of metastatic colorectal cancer (mCRC). While initial studies focused on the treatment of disease that was refractory to available chemotherapy agents, 2 recent themes have emerged: the use of KRAS mutation status to sel...

journal_title：Clinical colorectal cancer

authors： Stein S,Cohen DJ,Hochster HS

更新日期：2010-06-01 00:00:00

abstract：BACKGROUND:Systemic chemotherapy increases the possibility of resection in patients with initially unresectable colorectal cancer (CRC), especially patients with hepatic metastasis. However, the predictive factors and prognosis of conversion to resection after chemotherapy in patients with various organ metastases rema...

journal_title：Clinical colorectal cancer

authors： Nozawa H,Ishihara S,Kawai K,Hata K,Kiyomatsu T,Tanaka T,Nishikawa T,Otani K,Yasuda K,Sasaki K,Kaneko M,Murono K

更新日期：2018-03-01 00:00:00

abstract：:Replacing infusional 5-fluorouracil (5-FU) leucovorin (LV) with oral capecitabine would be more convenient to patients, because it would lead to reduced hospital chair time and infusion-related toxicities. Previous trials with oral capecitabine-based regimens (other than XELOX [capecitabine/oxaliplatin]) have failed t...

journal_title：Clinical colorectal cancer

authors： Tyagi P,Grothey A

更新日期：2006-11-01 00:00:00

abstract：BACKGROUND:Quinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC). This phase 1b trial evaluated the combination of quinacrine plus capecitabine in patients with treatment-refractory mCRC. PATIENTS AND METHODS:Using a modified Simon accelerated titration design, adults with...

journal_title：Clinical colorectal cancer

authors： Winer A,Denlinger CS,Vijayvergia N,Cohen SJ,Astaturov I,Dotan E,Gallant JN,Wang EW,Kunkel M,Lim B,Harvey HA,Sivik J,Korzekwa K,Ruth K,White K,Cooper HS,Ross EA,Zhou L,El-Deiry WS

更新日期：2020-08-19 00:00:00

abstract：:Primary squamous cell colorectal carcinomas are uncommon, and their characteristics are not well known. They seem to occur most commonly in the fifth decade of life with a slight predominance for men. The most commonly reported anatomic locations are the rectum and the proximal colon. Clinical features and common diag...

journal_title：Clinical colorectal cancer

authors： Copur S,Ledakis P,Novinski D,Mleczko KL,Frankforter S,Bolton M,Fruehling RM,VanWie E,Norvell M,Muhvic J

更新日期：2001-05-01 00:00:00

abstract：:Thymidylate synthase (TS) is a key enzyme in the synthesis of 2'-deoxythymidine-5'-monophosphate, an essential precursor for DNA biosynthesis. For this reason, this enzyme is a critical target in cancer chemotherapy. As the first TS inhibitor in clinical use, 5-fluorouracil (5-FU) remains widely used for the treatment...

journal_title：Clinical colorectal cancer

authors： Rose MG,Farrell MP,Schmitz JC

更新日期：2002-02-01 00:00:00

abstract：BACKGROUND:As of 2006, bevacizumab was available for the treatment of metastatic colorectal cancer (mCRC) in British Columbia (BC). This study compares survival between referred patients diagnosed with mCRC in 2003/2004 (pre-bevacizumab era) and 2006 (bevacizumab era). PATIENTS AND METHODS:The BC cancer agency (BCCA) ...

journal_title：Clinical colorectal cancer

authors： Renouf DJ,Lim HJ,Speers C,Villa D,Gill S,Blanke CD,O'Reilly SE,Kennecke H

更新日期：2011-06-01 00:00:00

abstract：:Hepatic colorectal metastases present a challenging problem in patients with recurrent colorectal cancer. Twenty percent of patients with recurrence will have liver metastases as a component of their disease, and only 10% of these patients will have isolated liver metastases that are resectable. Although systemic chem...

journal_title：Clinical colorectal cancer

authors： Meyers MO,Sasson AR,Sigurdson ER

更新日期：2003-05-01 00:00:00

abstract：INTRODUCTION:Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU. Given the additional benefit of oxaliplatin over FP alone in the management of color...

journal_title：Clinical colorectal cancer

authors： Chakrabarti S,Sara J,Lobo R,Eiring R,Finnes H,Mitchell J,Hartgers M,Okano A,Halfdanarson T,Grothey A

更新日期：2019-03-01 00:00:00

abstract：UNLABELLED:Patients with colorectal cancer (CRC) and renal cell carcinoma (RCC) may be at risk for additional primary malignancies. A review of 101 patients with these concurrent diagnoses was performed. Forty-two percent of patients had 1 or more additional malignancies; none appeared to be associated with Lynch syndr...

journal_title：Clinical colorectal cancer

authors： Steinhagen E,Moore HG,Lee-Kong SA,Shia J,Eaton A,Markowitz AJ,Russo P,Guillem JG

更新日期：2013-03-01 00:00:00

abstract：BACKGROUND:Adenocarcinoma of the vermiform appendix is rare. It constitutes less than 0.5% of all gastrointestinal malignancies. Pathologically, appendiceal neoplasms are categorized into various subtypes depending on cell lineage. PATIENTS AND METHODS:We considered a case series of appendiceal invasive adenocarcinoma...

journal_title：Clinical colorectal cancer

authors： Bunni J,Arnold D,Shelley-Fraser G,Shabbir J

更新日期：2015-03-01 00:00:00

abstract：BACKGROUND:In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer. PATIENTS AND METHODS...

journal_title：Clinical colorectal cancer

authors： Wolpin BM,Clark JW,Meyerhardt JA,Earle CC,Ryan DP,Enzinger PC,Zhu AX,Blaszkowsky L,Battu S,Fuchs CS

更新日期：2006-09-01 00:00:00

abstract：:Colorectal cancer (CRC), one of the most common malignancies worldwide, is often diagnosed at an advanced stage, and resistance to chemotherapeutic and existing targeted therapy is a major obstacle to its successful treatment. New targets that offer alternative clinical options are therefore urgently needed. Recently,...

journal_title：Clinical colorectal cancer

authors： Diogo V,Teixeira J,Silva PM,Bousbaa H

更新日期：2017-03-01 00:00:00

abstract：BACKGROUND:Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Their real-life evaluation is insufficient, especially in elderly and frail patients. The aim was to describe use, safety, and effectiveness of targeted therapies in first-line mCRC treatment according to age. PATIENTS AND...

journal_title：Clinical colorectal cancer

authors： Gouverneur A,Coutureau J,Jové J,Rouyer M,Grelaud A,Duc S,Gérard S,Smith D,Ravaud A,Droz C,Bernard MA,Lassalle R,Forrier-Réglat A,Noize P,ETNA study group and the EREBUS study group.

更新日期：2019-03-01 00:00:00

abstract：INTRODUCTION:In studies of colorectal cancer, the elderly have been frequently underrepresented because comorbid conditions and functional status often lead to study exclusion. For elderly patients with an indication for neoadjuvant chemoradiotherapy (nCRT), physicians usually decide using clinical factors whether nCRT...

journal_title：Clinical colorectal cancer

authors： Jacobs L,van der Vlies E,Ten Bokkel Huinink D,Bloemendal H,Intven M,Smits AB,Weusten BLAM,Siersema PD,van Lelyveld N,Los M

更新日期：2018-09-01 00:00:00

abstract：:Vascular endothelial growth factor (VEGF) is the driving force behind angiogenesis in most solid malignancies. This also holds true for colorectal cancer (CRC), where increased levels of VEGF in primary cancers are associated with increased microvessel density and poor prognosis. These findings have led to preclinical...

journal_title：Clinical colorectal cancer

authors： Ellis LM

更新日期：2004-10-01 00:00:00

abstract：:Regimens based on flouropyrimidines (eg, 5-fluorouracil [5-FU] and capecitabine) are the mainstay of chemotherapy for several malignancies, including colon, pancreatic, upper gastrointestinal, and breast cancers. Warfarin is one of the most commonly used oral anticoagulants. Patients receiving concomitant capecitabine...

journal_title：Clinical colorectal cancer

authors： Saif MW

更新日期：2005-09-01 00:00:00

abstract：:The standard in rectal cancer has been to add adjuvant radiation therapy to surgery in patients with stage II and III disease. Total mesorectal excision has led to lower local recurrence rates, and, if properly performed, may make adjuvant radiation unnecessary for certain stage II and III patients, such as T3 N0 pati...

journal_title：Clinical colorectal cancer

authors： Bechtel J,Tepper J

更新日期：2003-02-01 00:00:00

abstract：:Significant advances have been made with respect to our understanding of the critical role of agents targeting angiogenic pathways in the treatment of metastatic colorectal cancer (mCRC). The approval of 3 agents that target angiogenic signaling, bevacizumab, ziv-aflibercept, and regorafenib, provides strong evidence ...

journal_title：Clinical colorectal cancer

authors： Lee JJ,Chu E

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:Gemcitabine-related pneumonitis (GRP) has been reported relatively frequently for pancreas cancer in the literature; however, underlying risk factors and optimal management remain to be defined. We studied a cohort of patients with GRP and investigated potential predisposing factors in pancreatic cancer pati...

journal_title：Clinical colorectal cancer

authors： Sahin IH,Geyer AI,Kelly DW,O'Reilly EM

更新日期：2016-03-01 00:00:00

abstract：INTRODUCTION:The aim of this study was to evaluate the efficacy and toxicity of molecular targeted agents plus chemotherapy compared with chemotherapy alone as second-line therapy for patients with metastatic colorectal cancer (mCRC). MATERIALS AND METHODS:We identified randomized controlled trials that compared molec...

journal_title：Clinical colorectal cancer

authors： Pei X,Liu Y,Sun L,Zhang J,Fang Y,Liao X,Liu J,Zhang C,Yin T

更新日期：2016-12-01 00:00:00

abstract：:This article reviews the current status of the topoisomerase I (top I) inhibitors in the treatment of gastrointestinal (GI) malignancies. We focus on oral drug administration, the mode of administration that is generally preferred by patients with cancer. However, the great majority of the studies have been performed ...

journal_title：Clinical colorectal cancer

authors： Kuppens IE,Beijnen J,Schellens JH

更新日期：2004-09-01 00:00:00

abstract：BACKGROUND:Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-r...

journal_title：Clinical colorectal cancer

authors： Sunakawa Y,Yang D,Cao S,Zhang W,Moran M,Astrow SH,Hsiang J,Stephens C,Tsuji A,Takahashi T,Tanioka H,Negoro Y,Takagane A,Tani S,Yamaguchi T,Eto T,Fujii M,Ichikawa W,Lenz HJ

更新日期：2018-12-01 00:00:00

abstract：:This phase II study was designed to characterize the clinical activity of ISIS 3521 in patients with metastatic colorectal cancer (CRC). Sixteen patients with pretreated or refractory CRC were treated with ISIS 3521. Eleven patients were given a dose of 2.0 mg/kg per day, and 5 patients received 3.0 mg/kg per day give...

journal_title：Clinical colorectal cancer

authors： Marshall JL,Eisenberg SG,Johnson MD,Hanfelt J,Dorr FA,El-Ashry D,Oberst M,Fuxman Y,Holmlund J,Malik S

更新日期：2004-11-01 00:00:00

abstract：:Microbiome (microbiota) is a community of all microorganisms inhabiting a specific site of the body, including pathogens, which distinguishes it from the physiological microflora. Intestinal dysbiosis plays a key role in the development of colorectal cancer. In the process of carcinogenesis, inflammation, immune respo...

journal_title：Clinical colorectal cancer

authors： Wieczorska K,Stolarek M,Stec R

更新日期：2020-03-01 00:00:00

abstract：PURPOSE:Our purpose is to perform a comprehensive literature review of the use of levoleucovorin in gastrointestinal malignancies and to assess whether levoleucovorin is a reasonable alternative to racemic leucovorin. DESIGN:This is an extensive literature review of levoleucovorin use in patients with gastrointestinal...

journal_title：Clinical colorectal cancer

authors： Kovoor PA,Karim SM,Marshall JL

更新日期：2009-10-01 00:00:00